JP6089042B2 - 糖尿病及び関連症状の治療のための方法及び組成物 - Google Patents

糖尿病及び関連症状の治療のための方法及び組成物 Download PDF

Info

Publication number
JP6089042B2
JP6089042B2 JP2014542296A JP2014542296A JP6089042B2 JP 6089042 B2 JP6089042 B2 JP 6089042B2 JP 2014542296 A JP2014542296 A JP 2014542296A JP 2014542296 A JP2014542296 A JP 2014542296A JP 6089042 B2 JP6089042 B2 JP 6089042B2
Authority
JP
Japan
Prior art keywords
glutamine
diabetes
salt
compositions
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014542296A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533689A (ja
JP2014533689A5 (enExample
Inventor
ニイハラ，ユタカ
Original Assignee
エマウス メディカル インコーポレイテッド
エマウス メディカル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6089042(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エマウス メディカル インコーポレイテッド, エマウス メディカル インコーポレイテッド filed Critical エマウス メディカル インコーポレイテッド
Publication of JP2014533689A publication Critical patent/JP2014533689A/ja
Publication of JP2014533689A5 publication Critical patent/JP2014533689A5/ja
Application granted granted Critical
Publication of JP6089042B2 publication Critical patent/JP6089042B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2014542296A 2011-11-21 2012-11-17 糖尿病及び関連症状の治療のための方法及び組成物 Expired - Fee Related JP6089042B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
US61/629,633 2011-11-21
PCT/US2012/000557 WO2013077893A1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016207931A Division JP6389495B2 (ja) 2011-11-21 2016-10-24 糖尿病及び関連症状の治療のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2014533689A JP2014533689A (ja) 2014-12-15
JP2014533689A5 JP2014533689A5 (enExample) 2015-01-29
JP6089042B2 true JP6089042B2 (ja) 2017-03-01

Family

ID=48470183

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014542296A Expired - Fee Related JP6089042B2 (ja) 2011-11-21 2012-11-17 糖尿病及び関連症状の治療のための方法及び組成物
JP2016207931A Expired - Fee Related JP6389495B2 (ja) 2011-11-21 2016-10-24 糖尿病及び関連症状の治療のための方法及び組成物
JP2018041934A Expired - Fee Related JP6550160B2 (ja) 2011-11-21 2018-03-08 糖尿病及び関連症状の治療のための方法及び組成物
JP2018153440A Pending JP2018199692A (ja) 2011-11-21 2018-08-17 糖尿病及び関連症状の治療のための方法及び組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016207931A Expired - Fee Related JP6389495B2 (ja) 2011-11-21 2016-10-24 糖尿病及び関連症状の治療のための方法及び組成物
JP2018041934A Expired - Fee Related JP6550160B2 (ja) 2011-11-21 2018-03-08 糖尿病及び関連症状の治療のための方法及び組成物
JP2018153440A Pending JP2018199692A (ja) 2011-11-21 2018-08-17 糖尿病及び関連症状の治療のための方法及び組成物

Country Status (10)

Country Link
US (2) US20130143968A1 (enExample)
EP (2) EP2782588B1 (enExample)
JP (4) JP6089042B2 (enExample)
CN (3) CN103945858A (enExample)
BR (1) BR112014011898A2 (enExample)
ES (1) ES2785094T3 (enExample)
HK (1) HK1257401A1 (enExample)
IN (1) IN2014KN01037A (enExample)
PH (2) PH12020550726B1 (enExample)
WO (1) WO2013077893A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2003072556A1 (en) * 2001-06-27 2003-09-04 Prosidion Ltd. Glutaminyl based dpiv inhibitors
SE0201713D0 (sv) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CA2774197A1 (en) * 2006-04-22 2008-04-03 Harbor Biosciences, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
WO2008038771A1 (en) * 2006-09-29 2008-04-03 Ajinomoto Co., Inc. Glutamine-containing composition for increasing blood flow
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
HUE034551T2 (en) * 2009-01-12 2018-02-28 Biokier Inc Composition and method for treatment of diabetes
NL1036746C2 (nl) * 2009-03-20 2010-09-21 Glnp Holding B.V. Kit van onderdelen bevattende l-glutamine en egcg.
MX2012003459A (es) * 2009-09-23 2012-05-22 Biokier Inc Composicion y metodo para el tratamiento de la diabetes.

Also Published As

Publication number Publication date
CN103945858A (zh) 2014-07-23
HK1257401A1 (zh) 2019-10-18
EP2782588A1 (en) 2014-10-01
JP6389495B2 (ja) 2018-09-12
BR112014011898A2 (pt) 2017-05-16
JP2014533689A (ja) 2014-12-15
PH12020550726A1 (en) 2021-06-14
US20190192463A1 (en) 2019-06-27
EP3437649A1 (en) 2019-02-06
PH12014501052B1 (en) 2020-10-09
PH12014501052A1 (en) 2014-06-30
JP2018199692A (ja) 2018-12-20
JP6550160B2 (ja) 2019-07-24
CN108354916A (zh) 2018-08-03
EP2782588A4 (en) 2015-05-20
PH12020550726B1 (en) 2022-11-09
ES2785094T3 (es) 2020-10-05
US20130143968A1 (en) 2013-06-06
IN2014KN01037A (enExample) 2015-10-09
CN108478551A (zh) 2018-09-04
JP2018115175A (ja) 2018-07-26
JP2017052766A (ja) 2017-03-16
EP2782588B1 (en) 2020-04-15
WO2013077893A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
JP5000493B2 (ja) インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット
KR102188487B1 (ko) 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
KR20080106455A (ko) 대사장애의 조합치료
WO2006094933A1 (en) Roflumilast for the treatment of diabetes mellitus
JP6550160B2 (ja) 糖尿病及び関連症状の治療のための方法及び組成物
JP2017519028A (ja) 重度の高トリグリセリド血症の処置
JP4804353B2 (ja) 糖尿病の治療及び予防のためのフタリド誘導体の使用
CN103402506A (zh) 用于治疗糖尿病的组合
EP3081097B1 (en) Composition for the treatment of infertility
TW201740933A (zh) (r)-(+)-維拉帕米用於治療高血糖的用途
JP5063369B2 (ja) メグリチニド類を含有する肝臓線維化予防用医薬組成物
US20150150855A1 (en) Method of improving liver function
JPWO2007007757A1 (ja) ＰＰＡＲγアゴニストを含有する医薬組成物
JP2021520403A (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
US20060121034A1 (en) Treatment for alzheimer's disease and related conditions
EP1731170A1 (en) Therapeutic agent for diabetes containing insulin resistance improving agent
TWI461192B (zh) 降低血脂異常病患之糖化血色素的醫藥組成物
KR20070102694A (ko) 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
HK1094314A (en) Therapeutic agent for diabetes containing insulin resistance improving agent
KR20200140384A (ko) 글리타존 및 nrf2 활성화제를 포함하는 약학 조성물
HK1111620A (en) Pharmaceutical composition containing ppar gamma agonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160204

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161024

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170206

R150 Certificate of patent or registration of utility model

Ref document number: 6089042

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees